Prestige Consumer Healthcare Inc.

PBH Healthcare Drug Manufacturers Specialty & Generic

Prestige Consumer Healthcare Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 billion, down 4.31% from fiscal 2025. In the quarter to June 2026, revenue grew 6.48%, EPS fell 36.5%, free cash flow fell 14.2% and total debt rose 100.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

49.92 0.72 +1.46%
Market cap
$2.3B
P/E
13.9×
Fwd P/E
10.3×
Dividend yield
—
F-score
5/9
Altman Z
2.48
Beneish M
−2.53
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
13.17 15.04 16.19 15.37

+8 more quarters

P/S ratio
2.03 2.64 2.68 2.75
P/FCF ratio
9.53 11.65 11.05 11.98
P/Operating CF
31.69 67.04 37.73 53.22
P/B ratio
1.17 1.52 1.61 1.68
EV/Sales
3.79 3.52 3.58 3.57
EV/EBITDA
12.92 11.18 11.16 10.92
EV/FCF
17.80 15.54 14.80 15.51
Current Ratio
3.23 3.57 3.11 3.70
Net Debt/EBITDA
31.52 11.25 10.93 10.18
Debt/Equity
1.06 0.54 0.58 0.55
Earnings Yield
7.59% 6.65% 6.18% 6.51%
Free Cash Flow Yield
10.49% 8.58% 9.05% 8.35%
Free Cash Flow per Share
1.41 0.78 1.57 1.13
Book value per Share
40.38 38.95 38.21 37.23
Free Cash Flow
67.09 37.63 75.26 55.38
EV/EBIT
14.44 12.38 12.26 11.94
Other line items

Show all line items

Columns are period end dates